<DOC>
	<DOCNO>NCT00101179</DOCNO>
	<brief_summary>MS-275 may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , azacitidine , work different way stop growth cancer cell , either kill cell stop divide . Giving MS-275 together azacitidine may kill cancer cell . This phase I trial study side effect best dose MS-275 give together azacitidine treat patient myelodysplastic syndrome , chronic myelomonocytic leukemia , acute myeloid leukemia .</brief_summary>
	<brief_title>MS-275 Azacitidine Treating Patients With Myelodysplastic Syndromes , Chronic Myelomonocytic Leukemia , Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety toxicity MS-275 azacitidine patient myelodysplastic syndrome , chronic myelomonocytic leukemia , acute myeloid leukemia . II . Determine maximum tolerate dose optimal phase II dose MS-275 combined azacitidine patient . III . Determine , preliminarily , potential therapeutic activity regimen patient . IV . Correlate MS-275 pharmacokinetics clinical response laboratory correlative endpoint patient treat regimen . OUTLINE : This multicenter , dose-escalation study MS-275 . Patients receive azacitidine subcutaneously day 1-10 oral MS-275 day 3 10 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos MS-275 maximum tolerate dose ( MTD ) determine . Patients receive adjust dos azacitidine base clinical response . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Up 9 additional patient treat MTD . [ Note : Patients achieve hematologic improvement partial complete response stable disease 4 course therapy may receive additional 4 course therapy high dose originally assign ]</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Diagnosis 1 follow : Histologically confirm myelodysplastic syndrome ( MDS ) bone marrow aspiration and/or biopsy International Prognostic Scoring System ( IPSS ) score intermediate1 , intermediate2 , high International Prognostic Scoring System ( IPSS ) score intermediate1 , intermediate2 , high Low IPSS score allow provided patient clinically significant cytopenia ( i.e. , absolute neutrophil count &lt; 1,000/mm^3 , untransfused hemoglobin &lt; 8 g/dL , platelet count &lt; 20,000/mm^3 , anemia require transfusion ) Chronic myelomonocytic leukemia Acute myeloid leukemia ( AML ) Relapsed refractory disease Untreated AML allow provide patient meet &gt; = 1 follow criterion : Age 60 AML arise set antecedent hematologic disorder Highrisk cytogenetic abnormality Medical condition may compromise ability give cytotoxic chemotherapy primary modality Refused cytotoxic chemotherapy WBC &lt; 30,000/mm3 &gt; = 2 week study entry Acute promyelocytic leukemia allow provided patient least second relapse already receive treatment regimen contain arsenic trioxide isotretinoin No clinical evidence CNS pulmonary leukostasis CNS leukemia Peformance status : Zubrod 02 Life expectancy : At least 6 month Hematopoietic : See Disease Characteristics Hemoglobin â‰¥ 8 g/dL ( transfusion allow ) No disseminated intravascular coagulation Renal : Creatinine normal OR Creatinine clearance &gt; = 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study treatment No untreated , active infection No serious uncontrolled medical condition More 3 week since prior hematopoietic growth factor malignancy At least 3 week since prior hydroxyurea ( 2 week AML patient ) No concurrent hydroxyurea Recovered prior therapy At least 2 week since prior cytotoxic therapy ( AML patient ) More 3 week since prior therapy malignancy No concurrent investigational commercial agent therapy malignancy No concurrent valproic acid Hepatic : Bilirubin normal unless due hemolysis Gilbert 's syndrome AST ALT = &lt; 2.5 time upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>